Home › Compare › JVCZY vs ABBV
JVCZY yields 0.37% · ABBV yields 3.06%● Live data
📍 JVCZY pulled ahead of the other in Year 9
Combined, JVCZY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JVCZY + ABBV for your $10,000?
JVCKENWOOD Corporation manufactures and sells products in the mobility and telematics services, public service, and media service sectors in Japan and internationally. The Mobility & Telematics Services Sector segment manufactures and sells car AV systems, car navigation systems, car audio systems, dashcams, in-vehicle devices, etc., as well as telematics solutions. The Public Service Sector segment manufactures and sells professional wireless communications devices, video surveillance and audio equipment, medical image display systems, etc. The Media Service Sector segment offers professional video cameras, projectors, headphones, commercial video cameras, home audio equipment, portable power supplies, etc.; CDs and DVDs (packaged software), etc.; and audio and video software, content distribution, etc. The Others segment provides service parts, etc. The company also provides contract manufacturing service of electronic devices. The company sells its products under the JVC, Victor, and KENWOOD brands. The company was formerly known as JVC KENWOOD Holdings, Inc. and changed its name to JVCKENWOOD Corporation in August 2011. The company was founded in 1927 and is headquartered in Yokohama, Japan.
Full JVCZY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.